Compare MERC & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MERC | KRRO |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | Canada | United States |
| Employees | N/A | 87 |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 109.7M |
| IPO Year | 2005 | 2019 |
| Metric | MERC | KRRO |
|---|---|---|
| Price | $1.26 | $10.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $2.50 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 374.2K | 207.0K |
| Earning Date | 04-30-2026 | 03-12-2026 |
| Dividend Yield | ★ 11.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,169,145,000.00 | $6,392,000.00 |
| Revenue This Year | $13.75 | N/A |
| Revenue Next Year | $10.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 25.50 | ★ 181.46 |
| 52 Week Low | $1.27 | $5.20 |
| 52 Week High | $6.78 | $55.89 |
| Indicator | MERC | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 22.96 | 43.60 |
| Support Level | N/A | $10.55 |
| Resistance Level | $2.30 | $14.96 |
| Average True Range (ATR) | 0.10 | 0.89 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 4.31 | 6.50 |
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.